319 related articles for article (PubMed ID: 27084252)
1. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T; Fukuda T; Okumura H; Sunami K; Sawazaki A; Maeda Y; Tsurumi H; Uike N; Hidaka T; Takatsuka Y; Eto T; Tsuda H; Fujisaki T; Miyamoto T; Tsuneyoshi N; Iyama S; Nagafuji K; Harada M
Int J Hematol; 2016 Jun; 103(6):676-85. PubMed ID: 27084252
[TBL] [Abstract][Full Text] [Related]
2. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.
Han EJ; Lee SE; Kim SH; Sohn HS; Jung SE; Park G; Choi BO; Lee SN; Yang SW; Han K; Cho SG
Ann Hematol; 2011 Sep; 90(9):1075-82. PubMed ID: 21336624
[TBL] [Abstract][Full Text] [Related]
4. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
5. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
[TBL] [Abstract][Full Text] [Related]
6. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
7. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
8. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
10. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
11. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
[TBL] [Abstract][Full Text] [Related]
12. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Fitoussi O; Belhadj K; Mounier N; Parrens M; Tilly H; Salles G; Feugier P; Ferme C; Ysebaert L; Gabarre J; Herbrecht R; Janvier M; Van Den Neste E; Morschhauser F; Casasnovas O; Ghesquieres H; Anglaret B; Brechignac S; Haioun C; Gisselbrecht C
Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Barbui AM; Rossi A; Gritti G; Corradini P; Di Nicola M; Patti C; Mulé A; Zanni M; Zoli V; Billio A; Piccin A; Negri G; Castellino C; Di Raimondo F; Ferreri AJ; Benedetti F; La Nasa G; Gini G; Trentin L; Frezzato M; Flenghi L; Falorio S; Chilosi M; Bruna R; Tabanelli V; Pileri S; Masciulli A; Delaini F; Boschini C; Rambaldi A
J Clin Oncol; 2016 Nov; 34(33):4015-4022. PubMed ID: 28199143
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
16. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
Vitolo U; Chiappella A; Angelucci E; Rossi G; Liberati AM; Cabras MG; Botto B; Ciccone G; Gaidano G; Falchi L; Freilone R; Novero D; Orsucci L; Pavone V; Pogliani E; Rota-Scalabrini D; Salvi F; Tonso A; Tucci A; Levis A;
Haematologica; 2009 Sep; 94(9):1250-8. PubMed ID: 19586937
[TBL] [Abstract][Full Text] [Related]
17. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
[TBL] [Abstract][Full Text] [Related]
18. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
19. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
Inano S; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Arima N
Int J Hematol; 2014 Feb; 99(2):162-8. PubMed ID: 24338743
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
